Lonza joins Centre for Continuous Manufacturing and Advanced Crystallisation to enhance service offering
Lonza joined CMAC to enhance its service offering for specialty and enhanced drug product and particle technologies
Lonza will serve as a CMAC Translation to Industry Collaborator, reinforcing its commitment to advancing innovative manufacturing solutions
CMAC aims to accelerate the digital transformation of CMC development and manufacturing approaches to enable future drug substance and drug product supply
Lonza, a global development and manufacturing partner to the pharmaceutical and biotech markets, today announced it has joined CMAC, a world leading centre for medicines manufacturing research, to enhance its service offering for particle technologies and drug product development and manufacture.
Based at the University of Strathclyde in Scotland, CMAC is an international research hub with a unique configuration of academic and industrial leaders within applied and pre-competitive research programs, and translation to industry models. Driven by industry needs, it aims to transform pharmaceutical manufacturing and crystallization processes by developing continuous manufacturing technologies, optimizing efficiency, and enhancing product quality.
Through its membership, Lonza will gain access to CMAC’s unique network, which advances Chemistry, Manufacturing and Control (CMC) technologies, implements digitalization strategies and develops innovative continuous processing and crystallization solutions for active pharmaceutical ingredients and drug product technologies. Lonza’s participation in CMAC will ensure the effective application of research outcomes to strengthen CMC processes and their implementation for its customers.
Massimo Bresciani, CMAC Industry Director, commented:
‘‘Welcoming Lonza into CMAC marks a significant milestone in our mission to transform medicines manufacturing. Its global leadership, technical depth, and strategic vision will be instrumental in shaping and accelerating the adoption of highly automated manufacturing platforms and advanced CMC solutions. This collaboration reinforces our commitment to building a connected ecosystem where academic innovation and industrialists converge to translate cutting-edge research into impactful, scalable solutions for the pharmaceutical and biotech sectors.’’
Francois Ricard, Head of R&D, Advanced Synthesis, Lonza, added:
“Our participation in CMAC will allow us to work with world-leading industry and academia experts and apply best practice in the fields of API development, continuous processing, drug product development, and overall digital CMC strategy. Our global team will drive the implementation of these processes and technologies across scales in a CDMO setup for the benefit of our customers and partners.”
Additional Information
To learn more about Lonza’s Advanced Synthesis services, visit Lonza | Advanced Synthesis
About CMAC
CMAC is an internationally leading medicines manufacturing research centre with a unique configuration of academic research, applied, and pre-competitive programmes. Working in partnership with Tier 1, Tier 2, academic, and innovation partners, the goal of CMAC is to transform Medicines Development, Manufacture & Supply, and further grow its world-class portfolio of multi-disciplinary collaborative research. This includes the Digital Medicines Manufacturing Research Centre (DM²), Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP), UKRPIF Net Zero Pilot, UKRPIF CMAC Data Lab, and the CMAC Future Manufacturing Research Hub, along with training and translation projects within a world-class facility.
Lonza Contact Details
CMAC Contact Details
Disclaimer
Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory.
All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third party owners and are used only for informational purposes.
Privacy Policy link